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Abstract 
Background 
Despite evidence of chemotherapy’s ability to cure or comfort those with colon cancer, nearly 
half of such Americans do not receive it. African Americans (AA) seem particularly 
disadvantaged. An ethnicity by poverty by health insurance interaction was hypothesized 
such that the multiplicative disadvantage of being extremely poor and inadequately insured is 
worse for AAs than for non-Hispanic white Americans (NHWA). 
Methods 
California registry data were analyzed for 459 AAs and 3,001 NHWAs diagnosed with stage 
II to IV colon cancer between 1996 and 2000 and followed until 2011. Socioeconomic data 
from the 2000 census categorized neighborhoods: extremely poor (≥ 30% of households 
poor), middle (5-29% poor) and low poverty (< 5% poor). Participants were randomly 
selected from these poverty strata. Primary health insurers were Medicaid, Medicare, private 
or none. Chemotherapy rates were age and stage-adjusted and comparisons used standardized 
rate ratios (RR). Logistic and Cox regressions, respectively, modeled chemotherapy receipt 
and long term survival. 
Results 
A significant 3-way ethnicity by poverty by health insurance interaction effect on 
chemotherapy receipt was observed. Among those who did not live in extremely poor 
neighborhoods and were adequately insured privately or by Medicare, chemotherapy rates did 
not differ significantly between AAs (37.7%) and NHWAs (39.5%). Among those who lived 
in extremely poor neighborhoods and were inadequately insured by Medicaid or uninsured, 
AAs (14.6%) were nearly 60% less likely to receive chemotherapy than were NHWAs 
(25.5%, RR = 0.41). When the 3-way interaction effect as well as the main effects of poverty, 
health insurance and chemotherapy was accounted for, survival rates of AAs and NHWAs 
were the same. 
Conclusions 
The multiplicative barrier to colon cancer care that results from being extremely poor and 
inadequately insured is worse for AAs than it is for NHWAs. AAs are more prevalently poor, 
inadequately insured, and have fewer assets so they are probably less able to absorb the 
indirect and direct, but uncovered, costs of colon cancer care. Policy makers ought to be 
cognizant of these factors as they implement the Affordable Care Act and consider future 
health care reforms. 
Keywords 
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Background 
Chemotherapy provided after surgical resection is beneficial for many with non-localized 
colon cancer. Survival benefits are large for many with advanced, but non-metastasized, stage 
III disease and smaller, but still significant for some with stage II disease [1-3]. There are 
probably even small survival benefits of chemotherapy for people with metastasized, stage IV 
colon cancer, in addition to its clear palliative benefits [4]. Yet nearly half of all such people 
in the United States do not receive chemotherapy with the intention to either cure or comfort 
[5]. Moreover, chemotherapy access may be affected by social and economic characteristics 
such as race or ethnicity, and income and health insurance adequacy. African Americans 
(AA), who are also poorer and less adequately insured, on average, than non-Hispanic white 
Americans (NHWA), seem particularly disadvantaged [6,7]. They are less likely to receive 
adjuvant chemotherapy and this can explain much of their survival disadvantage [5,8-10]. 
Social and health care systemic factors seem most implicated in this racial divide for the 
following reasons. First, clinical studies of equal-access health care systems within the US 
have consistently observed similar chemotherapy and survival rates among AAs and NHWAs 
with colon cancer [11-14]. Second, colon cancer chemotherapy rates seem to be much higher 
in Canada than in the US [15,16]. Third, recent population-based studies of colon cancer care 
in California and Ontario suggested that people of color, including black people of various 
ethnic backgrounds, with colon cancer are much better served in California [16-18]. 
Moreover, health insurance inadequacies in the US versus universal coverage of medically 
necessary care in Canada largely explained the between-country divide. Being uninsured or 
insured by Medicaid has been consistently found to be less adequate than being insured by 
Medicare or by a private insurer [5,17,18]. Fourth, this field’s research syntheses allow for 
the conclusion that socioeconomic status (SES) and treatment differences largely explain 
observed AA-NHWA survival differences [5,8-10]. The fact that they have largely, but not 
completely accounted for racial differences with social-systemic factors suggests the 
plausibility of at least one of their causes being biological. For example, AA and NHWA 
patients may differ on oncogene-based tumor characteristics that affect survival directly or 
indirectly, through their effects upon clinicians’ decisions to prescribe chemotherapies. 
Modest equivocal differences between racialized groups on colon tumor grade [8], however, 
suggest that, though possible, this explanation for the differential uptake of chemotherapy and 
survival differences between AAs and NHWAs is improbable. 
In attempting to account for SES, this field’s population-based studies have typically used 
census data to define low-income neighborhoods. However, their lowest income 
neighborhoods only ranged from 10% to 20% poor. They therefore had limited power to 
study colon cancer care among the “truly disadvantaged” [19] who live, for example, in 
America’s poorest neighborhoods where 30% to 40% or more of households have incomes 
below the poverty line [19-21]. Consequently, they probably did not account for residual 
confounding. That is, their AA participants probably had substantially lower incomes than 
their NHWA counterparts, even in the lowest income neighborhoods studied [22,23]. This 
field also seems limited by its focus on the mere main effects of race/ethnicity, SES and 
health insurance. Recognizing that it is important to analyze different racial/ethnic minority 
groups uniquely, our previous research on breast cancer care among Mexican American 
women leads us to anticipate complex interactions of ethnicity, poverty and health insurance 
status [24-26]. We were recently presented with a serendipitous opportunity to systematically 
replicate that notion among AAs with colon cancer. 
We oversampled people with colon or breast cancer in the highest poverty neighborhoods of 
California for other primary studies [17,18,24]. This necessarily meant that we also 
oversampled AAs. Secondary to our original study’s intentions we had the opportunity to 
compare the chemotherapy and survival experiences of AAs and NHWAs with colon cancer 
while providing more control for residual confounding by SES than previous studies had. 
This field’s historical-theoretical context strongly suggests multiplicative, rather than additive 
disadvantages of being poor and inadequately insured among AAs. That is, the combined 
effects of being poor and of being uninsured or underinsured on colon cancer care are 
probably worse for AAs than for NHWAs. Therefore, we hypothesize a 3-way ethnicity by 
poverty by health insurance interaction on the receipt of chemotherapy. Secondarily, we 
hypothesize that this complex interaction, along with the main effects of poverty, health 
insurance adequacy and treatment access, will now completely explain any observed AA-
NHWA survival differences. 
Methods 
Six thousand, three hundred people who were diagnosed with colon cancer between 1996 and 
2000 were randomly selected from the California Cancer Registry (CCR) that was joined to 
the 2000 census by census tracts [17,18,27]. The original sample was also stratified by SES 
(extremely poor neighborhoods where 30% or more of the households were poor, 5% to 29% 
or less than 5% poor) and place (large or smaller urban or rural). This secondary analysis 
excluded localized, stage I cancers for which chemotherapy is not indicated as well as people 
of other racial or ethnic backgrounds [28,29]. This study then analyzed colon cancer care 
among 459 AAs (also non-Hispanic) and 3,001 NHWAs with stage II to IV disease. 
A logistic regression model was used to test the 3-way ethnicity (AA vs. NHWA) by poverty 
(extremely poor or not) by health insurance adequacy (uninsured or Medicaid insured vs. 
privately or Medicare insured) interaction in predicting binary chemotherapy receipt [30]. 
Odds ratios (OR) and 95% confidence intervals (CI) were estimated from regression 
statistics. AA study participants were younger (M = 67.4, SD = 13.9), on average, than the 
NHWA participants (M = 70.9, SD = 13.0), F (1, 3,458) = 28.39, p < .05. Therefore, all rates 
were internally age-adjusted and reported as percentages (rates per 100). Chemotherapy rates 
were also stage-adjusted as clinical indication and prescription rates differ significantly for 
stage II, III and IV disease. Then standardized rate ratios (RR) were reported for critical 
between-group comparisons with 95% CIs derived from the Mantel-Haenszel χ2 test. 
Standardized rate difference (RD) indices were also used to further aid the interpretation of 
practical-clinical significance. The hypothesis that the main and interacting effects of 
ethnicity, poverty, health insurance and chemotherapy access would completely explain any 
observed AA-NHWA survival difference was tested with unadjusted and adjusted Cox 
proportional hazards regression models [31]. All participants were minimally followed for 10 
years, from the date of their diagnosis until January 1, 2011. Hazard ratios (HR) and 95% CIs 
were estimated from regression statistics. Other methodological details have been reported 
[17,18,27]. This study was reviewed and cleared by the University of Windsor research ethics 
board. 
Results 
Description of AA and NHWA samples 
Unadjusted descriptive profiles of the AA and NHWA samples are displayed in Table 1. The 
statistically significant comparisons seem consistent with existing knowledge. AAs were 
much more likely to live in high poverty neighborhoods and seemed more likely to be either 
uninsured or to be insured by Medicaid. Interestingly, oversampling from poor 
neighborhoods seems to have provided ample control for SES and biological characteristics. 
Median annual household incomes among extremely poor AAs ($22,600) and NHWAs 
($23,650), though significantly different in a statistical sense, were actually quite similar. 
Overall, the two ethnic groups did not differ significantly on either tumor grade or on stage of 
disease at diagnoses. AAs seemed somewhat less likely to receive chemotherapy. 
Table 1 Socio-demographic and clinical characteristics of African American and non-
Hispanic white American colon cancer patients in California, 1996-2000 
 African American, No. (%) Non-Hispanic White, No. (%) 
Age at diagnosis,** y 
     25 - 59 129 28.1 563 18.8 
     60 - 69 99 21.6 629 21.0 
     70 - 79 138 30.1 980 32.7 
     ≥ 80 93 20.3 829 27.6 
Women** 275 59.9 1,574 52.4 
Neighborhood poverty prevalence,**% 
     < 5 31 6.8 1,240 41.3 
     5 - 29 76 16.6 1,131 37.7 
     ≥ 301 352 76.7 630 21.0 
Primary health insurers** 
     Private 194 42.3 1,409 47.0 
     Medicare 201 43.8 1,391 46.4 
     Medicaid 36 7.8 72 2.4 
     Uninsured 28 6.1 129 4.3 
Stage at diagnosis 
     II 184 40.1 1,270 42.3 
     III 132 28.8 927 30.9 
     IV 143 31.2 804 26.8 
Tumor grade 
     I 31 7.4 192 6.8 
     II 286 68.4 1,863 66.4 
     III or IV2 101 24.2 752 26.8 
     Missing data* 41 8.9 194 6.5 
Examined 12 or more RLN3 124 40.4 939 44.1 
     Missing data 9 2.8 67 3.0 
Received Chemotherapy* 145 31.7 1,124 37.6 
     Missing data 2 0.4 9 0.3 
Note. RLN, Regional lymph nodes. 
1
 Median annual household income for extremely poor AA ($22,600) and NHWA ($23,650) subsamples; 
median test [46], χ2 (1, N = 982) = 5.51, p < .05. 
2
 Only 23 (0.7%) of the tumors were undifferentiated or grade IV. 
3
 Stage IV metastasized disease excluded. 
*
 p < .10 and ** p < .05 for between-ethnic group difference (χ2 test). 
Age-adjusted comparisons served to clarify the socioeconomic divide between AAs and 
NHWAs. AA patients (77.3%) were nearly four times as likely as NHWA patients (20.9%) to 
live in extremely poor neighborhoods (RR = 3.70, 95% CI 3.33, 4.11), they were nearly twice 
as likely to be either uninsured to Medicaid-insured (12.0% vs. 6.9%, RR = 1.74, 95% CI 
1.31, 2.31) while they were 17% less likely to be privately insured (39.4% vs. 47.5%, RR = 
0.83, 95% CI 0.74, 0.93). While one of every nine AA study participants (11.3%) suffered the 
multiplicative disadvantage of living in an extremely poor neighborhood and being 
inadequately insured, only one of every 36 NHWA participants was so disadvantaged (RR = 
4.03, 95% CI 2.97, 5.48). Finally, the AA patients were 26% less likely to receive 
chemotherapy (age- and stage-adjusted rates of 28.2% vs. 38.2%, RR = 0.74, 95% CI 0.63, 
0.85). It should be noted that nearly all (99.0%) of the patients with stage II or III disease 
received surgical resections. Fewer with stage IV disease had surgery, and among them fewer 
of the AA (60.1%) than NHWA (73.1%) patients were so treated (RR = 0.82, 95% CI 0.73, 
0.93). However, surgery refusal rates (5.5%) were identical for the AAs and NHWAs with 
metastasized disease. 
Ethnicity by poverty by health insurance interaction 
As hypothesized, a significant 3-way ethnicity by poverty by health insurance interaction was 
detected (OR = 1.46, 95% CI 1.04, 2.06) with an age, stage and grade-adjusted logistic 
regression on chemotherapy receipt that included the well-known main disadvantaging 
effects of being AA (OR = 0.64, 95% CI 0.48, 0.84), extremely poor (OR = 0.70, 95% CI 
0.58, 0.85) and inadequately insured (OR = 0.60, 95% CI 0.40, 0.89). Neither main or 
interacting effects of gender nor the number of region lymph nodes examined entered the 
model. As interpretation of the 3-way interaction effect’s point-estimate (OR = 1.46) is not 
intuitive, the interaction is practically depicted in Table 2. At the top of the table it can be 
seen that among those who did not live in extremely poor neighborhoods and were 
adequately insured, chemotherapy rates did not differ significantly between AAs and 
NHWAs. Moving down the table one sees that among those with one of two disadvantages, 
AAs were 20% less likely to receive chemotherapy (RR = 0.80). And at the bottom of the 
table we see that among the multiply disadvantaged, the disadvantaging effect on 
chemotherapy access appeared multiplicative. Among them AAs were nearly 60% less likely 
to receive chemotherapy than were NHWAs (RR = 0.41). One should note that chemotherapy 
refusal rates did not differ between these, most disadvantaged, AA (5.9%) and NHWA 
(6.3%) patients; χ2 (1, N = 130) = 0.01, p = .92. 
Table 2 Effects of the interaction of ethnicity, neighborhood poverty and health 
insurance on chemotherapy receipt in California, 1996-2000 
 
No.1 Rate RR2 (95% CI) 
NHWA-AA 
Chemotherapy RD 
< 30% Poor & Adequately Insured 
     Non-Hispanic white American 2,249 .395 1.00   
     African American 94 .377 0.95 (0.75, 1.20) 1.8% 
Intermediate Groups3 
     Non-Hispanic white American 673 .345 1.00   
     African American 314 .277 0.80 (0.65, 0.98) 6.8% 
≥ 30% Poor & Inadequately Insured 
     Non-Hispanic white American 79 .352 1.00   
     African American 51 .146 0.41 (0.22, 0.78) 20.6% 
Notes. NHWA, Non-Hispanic white American; AA, African American; RR, Standardized rate ratio; RD, Standardized rate 
difference; CI, Confidence interval. All rates were directly age and stage-adjusted using this study’s combined AA-NHWA 
population of cases as the standard. 
1
 Number of incident colon cancer cases. 
2
 A rate ratio of 1.00 was the within-ethnic group baseline. 
3
 Included those who lived in extremely poor neighborhoods, but were adequately insured or those who lived in less poor 
neighborhoods, but were inadequately insured. 
The multiplicative disadvantage of extremely poor and inadequately insured AAs is depicted 
in another, perhaps more clinically telling way, in the table’s right column. The NHWA-AA 
RD on chemotherapy receipt was 1.8% among the most advantaged group. While the RD of 
20.6% among the most disadvantaged group was more than a 10-fold multiple of that 
baseline difference. Such seems indicative of a huge chemotherapy access barrier. The 
support we found for our secondary hypothesis strongly suggests though that it can be 
effectively remediated. An age, gender, stage and grade-adjusted Cox regression on survival 
found that the AA patients were much more likely to die over the 10 year follow-up period 
(HR = 1.26, 95% CI 1.13, 1.42). When another model was run in which the main effects of 
poverty, health insurance and chemotherapy as well as the interaction effect of ethnicity-
poverty-health insurance were entered, AAs and NHWAs experienced identical risks of death 
(HR = 1.01, 95% CI 0.71, 1.43). 
Discussion 
First, this field’s established ethnicity-outcome relationships were systematically replicated 
among historical cohorts of AAs and NHWAs with non-localized colon cancer. This study’s 
AA participants were about 25% less likely to receive chemotherapy and about 25% more 
likely to die over the 10 years following their diagnosis than were its NHWA participants. 
Next, this field’s well-known main predictive effects were replicated. AAs, those who lived 
in extremely poor neighborhoods and those who were inadequately insured were all 
significantly less likely than NHWAs, the less poor or the adequately insured to receive 
chemotherapy and so more likely to die sooner. Then an ethnicity by poverty by health 
insurance interaction on chemotherapy receipt was discovered. This study’s central original 
finding, the 3-way interaction is evidence of the multiplicative disadvantage experienced by 
extremely poor and inadequately insured AAs seeking colon cancer care. Among relatively 
advantaged people, AA and NHWA chemotherapy rates differ little, if at all (< 2%). 
However, among the multiply disadvantaged extremely poor and inadequately insured, the 
AA-NHWA chemotherapy RD (> 20%) could, we think, be fairly characterized as huge in 
terms of both its clinical and human significance. Finally, controlling for residual SES 
confounding by oversampling from extremely poor neighborhoods and further controlling for 
demographic and biological differences through mathematical modeling, we discovered that 
the main and interacting effects of poverty, health insurance adequacy and treatment access 
can completely account for the typically observed AA-NHWA survival differences. After we 
accounted for such social forces, the survival experiences of the AA and NHWA colon 
cancer patients we studied were essentially identical. 
Two-way poverty by health insurance interactions have previously been observed in studies 
of breast and colon cancer care among NHWAs [18,24,25]. The beneficial effects of health 
insurance were observed to be strongest in low poverty neighborhoods. It was theorized that 
the effectiveness of health insurance programs was positively impacted by the availability of 
other key resources. In more affluent neighborhoods, where social and economic capital 
abounds, most people with cancer seemed able to absorb the indirect (time lost from work, 
recuperation, transportation and others) and direct, but additional uncovered, out-of-pocket 
costs of care (co-insurance and co-payments). Within high poverty neighborhoods on the 
other hand, relatively lacking in such capital reserves, health insurance programs seemed to 
be much less effective. Such extremely poor people were probably much less able to pick-up 
the co-insurance costs and co-payments that are prevalent in American cancer care. The 3-
way ethnicity-poverty-health insurance interaction observed in this study may be thought of 
as an extension of the previously observed 2-way poverty-health insurance interaction. It 
strongly suggests that the 2-way interaction’s effect is stronger for AAs. Their relative lack of 
capital reserves could explain this differential ethnic effect [32,33]. We saw that this study’s 
oversampling from extremely poor neighborhoods seemed to fairly well control AA-NHWA 
differences on depth of impoverishment [22,23], at least in terms of their annual household 
incomes that only differed by about $1,000. However, a contemporaneous analysis found that 
among the poorest households in America, NHWAs typically held $10,000 worth of equity, 
while AAs typically had no assets at all [7]. It seems probable that their lack of capital 
reserves operates to further potentiate the disadvantages already experienced by extremely 
poor and inadequately insured AAs as they try to purchase chemotherapeutic and other colon 
cancer care services. 
Practical—clinical and policy—significance 
Approximately 13,300 AAs are diagnosed with colon cancer each year [34,35]. 
Unfortunately, they quite commonly live in poor, often extremely poor, neighborhoods (one 
of every four or five households) and are also commonly uninsured or underinsured (one of 
every three or four households) [6,20]. Applying this study’s chemotherapy estimates to these 
population parameters and social exposures we estimate that each year slightly more than 
1,500 AAs with colon cancer are treated less optimally than are NHWAs of similar ages with 
colon cancers of similar stages and grades [36]. That represents 22,500 relatively 
undertreated AAs with colon cancer during the 15 years that preceded passage of the Patient 
Protection and Affordable Care Act, so-called Obamacare. This striking inequity is probably 
only the tip of the iceberg of AA disadvantages as colon cancer accounts for less than 3% of 
the burden of disease in the US [37]. One should hope that as Obamacare is rolled out and 
provides millions more Americans with health insurance that it will also diminish the racial 
and ethnic divides that presently exist in American health care. Such will probably depend 
largely upon the adequacy of the new health insurances it provides. Health care reformers 
need to account for the fact that even covered health care, especially for such diseases as 
colon cancer [38], has myriad out-of-pocket costs. Health insurance programs that serve to 
minimize such costs will necessarily be more effective than those that do not. 
Potential limitations 
This study could have been limited by incomplete information on chemotherapy. Because 
chemotherapy is most often received as an outpatient it can be more challenging for cancer 
registries to survey. For the following reasons we think it not a potent alternative explanation. 
First, the CCR has been demonstrated to be mostly complete (81% to 84%) on chemotherapy 
and errors have been demonstrated not to differ significantly by race/ethnicity or income 
[39,40]. Second, missing chemotherapy data was modest and did not differ between this 
study’s AA and NHWA samples. Third, analyses of health insurance, surgeries and survival 
were unlikely to have been affected [40-43] and modest errors very likely did not differ by 
socioeconomic factors [41]. Such nondifferential errors suggest that any bias would probably 
have been toward the null [44,45]. That is, the magnitude of this study’s observed AA 
disadvantages may, in fact, be underestimates of the truth. 
This study’s findings could also have been confounded by comorbid differences between its 
AA and NHWA samples. The CCR did not code comorbidities that are well known to be 
associated with socioeconomic factors, colon cancer care and survival [5]. However, AAs 
and NHWAs with similar disease stages were compared and through mathematical modeling, 
essentially matched on a proxy of cancer virulence, tumor grade, and on two strong correlates 
of other chronic diseases, age and poverty. Therefore, the two groups seemed to be quite 
similarly diseased, making comorbid alternative explanations unlikely. 
Conclusions 
Overall, AAs with non-localized colon cancer are 25% less likely to receive indicated 
chemotherapy than are NHWAs with similar colon cancers. Among the extremely poor and 
inadequately insured AAs are 60% less likely than NHWAs to receive such care. Ethnicity, 
poverty and health insurance status appear to interact in such a way that the multiplicative 
barriers to care of being extremely poor and inadequately insured are worse for AAs than 
they are for NHWAs. AAs are more prevalently poor and inadequately insured, but even 
when depth of income-based poverty is controlled, they still have substantially fewer assets 
than NHWAs so they are probably much less able to absorb the indirect and direct, but 
uncovered, costs of colon cancer care. Policy makers ought to be cognizant of these factors as 
they roll out Obamacare and consider future reforms of health care in America. 
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
KMG conceptualized the study, led the study design and writing and supervised the analysis. 
SH performed the analysis and assisted with study design, data interpretation and writing. 
INL, EB, FCW and SMK assisted with study design, data interpretation and writing. KMG 
and INL also obtained funding. All authors read and approved the final manuscript. 
Acknowledgements 
This research was supported in part with funds from the Canadian Institutes of Health 
Research (grant no. 67161–2). The authors gratefully acknowledge the administrative and 
logistical assistance of Kurt Snipes, Janet Bates and Gretchen Agha of the Cancer 
Surveillance and Research Branch, California Department of Public Health. We also 
gratefully acknowledge the research assistance of Mark Allen, Allyn Fernandez-Ami and Arti 
Parikh-Patel of the California Cancer Registry and Nancy Richter, Madhan Balagurusamy 
and Daniel Edelstein of the University of Windsor. We are also grateful for the assistance of 
Eric Holowaty of the University of Toronto, GuangYong Zou of the University of Western 
Ontario and Caroline Hamm of the Windsor Regional Cancer Center and the University of 
Western Ontario in obtaining funding. 
The collection of cancer incidence data used in this study was supported by the California 
Department of Public Health as part of the statewide cancer reporting program mandated by 
California Health and Safety Code Section 103885; the National Cancer Institute’s 
Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C 
awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C 
awarded to the University of Southern California, and contract HHSN261201000034C 
awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s 
National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the 
California Department of Public Health. The ideas expressed herein are those of the authors 
and endorsement by the State of California, the Department of Public Health, the National 
Cancer Institute and the Centers for Disease Control and Prevention or their contractors and 
subcontractors are not intended or should be inferred. 
References 
1. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini 
G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg 
RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon 
cancer: Who benefits and by how much? J Clin Oncol 2004, 22:1797–1806. 
2. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd 
LE, Seitz JF, Francini G: A pooled analysis of adjuvant chemotherapy for resected colon 
cancer in elderly patients. N Engl J Med 2001, 345:1091–1097. 
3. Figueredo A, Coombes ME, Mukherjee S: Adjuvant therapy for completely resected 
stage II colon cancer. Cochrane Database Syst Rev 2008:4. 
4. Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S: Supportive care for patients with 
gastrointestinal cancer. Cochrane Database Syst Rev 2009:4. 
5. Etzioni DA, El-Khoueiry AB, Beart RW Jr: Rates and predictors of chemotherapy use 
for stage III colon cancer: a systematic review. Cancer 2008, 113:3279–3289. 
6. DeNavas-Walt C, Proctor BD, Smith JC, US Census Bureau, Current Population Reports 
(P60-245): Income, Poverty, and Health Insurance Coverage in the United States: 2011. 
Washington, DC: US Government Printing Office; 2012. 
7. Conley D: Being Black, Living in the red: Race, Wealth, and Social Policy in America. Los 
Angeles, CA: University of California Press; 1999. 
8. Dimou A, Syrigos KN, Saif MW: Disparities in colorectal cancer in African-Americans 
vs whites: before and after diagnosis. World J Gastroenterol 2009, 15:3734–3743. 
9. Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O’Connell MJ, Benedetti JK, Saltz LB, 
Dignam JJ, Blackstock AW, ACCENT Collaborative Group: Outcomes among black 
patients with stage II and III colon cancer receiving chemotherapy: an analysis of 
ACCENT adjuvant trials. J Natl Cancer Inst 2011, 103:1498–1506. 
10. Du XL, Meyer TE, Franzini L: Meta-analysis of racial disparities in survival in 
association with socioeconomic status among men and women with colon cancer. Cancer 
2007, 109:2161–2170. 
11. Mack CD, Carpenter W, Meyer A, Sanoff H, Stürmer T: Racial disparities in receipt 
and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. 
Cancer 2012, 118:2925–2934. 
12. Berry J, Caplan L, Davis S, Minor P, Counts-Spriggs M, Glover R, Ogunlade V, Bumpers 
K, Kauh J, Brawley OW, Flowers C: A black-white comparison of the quality of stage-
specific colon cancer treatment. Cancer 2010, 116:713–722. 
13. Sabounchi S, Keihanian S, Anand BS: Impact of race on colorectal cancer. Clin 
Colorectal Cancer 2012, 11:66–70. 
14. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL: Racial disparities in 
cancer survival among randomized clinical trials patients of the Southwest Oncology 
Group. J Natl Cancer Inst 2009, 101:984–992. 
15. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, Gallinger S, Pollett 
WG: Concordance with clinical practice guidelines for adjuvant chemotherapy in 
patients with stage I–III colon cancer: Experience in 2 Canadian provinces. Can J Surg 
2009, 52:92–97. 
16. Gorey KM, Holowaty EJ, Fehringer G, Laukkanen E, Moskowitz A, Webster DJ, Richter 
NL: An international comparison of cancer survival: Toronto, Ontario, and Detroit, 
Michigan, metropolitan areas. Am J Public Health 1997, 87:1156–1163. 
17. Gorey KM, Luginaah IN, Bartfay E, Zou GY, Haji-Jama S, Holowaty EJ, Hamm C, 
Kanjeekal SM, Wright FC, Balagurusamy MK, Richter NL: Better colon cancer care for 
extremely poor Canadian women compared with American women. Health Soc Work 
2013, 38:240–248. 
18. Gorey KM, Luginaah IN, Holowaty EJ, Zou G, Hamm C, Bartfay E, Kanjeekal SM, 
Balagurusamy MK, Haji-Jama S, Wright FC: Effects of being uninsured or underinsured 
and living in high poverty neighborhoods on colon cancer care and survival in 
California: Historical cohort analysis, 1996—2011. BMC Public Health 2012, 12:897. 
19. Wilson WJ: The truly disadvantaged: The inner city, the underclass, and public policy. 
2nd edition. Chicago, IL: University of Chicago Press; 2012. 
20. Jargowsky PA: Stunning progress, hidden problems: The dramatic decline of 
concentrated poverty in the 1990s. In Redefining Urban and Suburban America: Evidence 
from Census 2000, Vol 2. Edited by Berube A, Katz B, Lang RE. Washington, DC: 
Brookings Institution Press; 2005:137–171. 
21. Jargowsky PA: Poverty and Place: Ghettos, Barrios, and the American City. New York: 
Russell Sage Foundation; 1997. 
22. Iceland J: Poverty in America: A Handbook. Los Angeles, CA: University of California 
Press; 2003. 
23. Dalaker J, US Census Bureau, Current Population Reports (P60-214): Poverty in the 
United States: 2000. Washington, DC: US Government Printing Office; 2001. 
24. Gorey KM, Luginaah IN, Holowaty EJ, Zou GY, Hamm C, Balagurusamy MK: 
Mediation of the effects of living in extremely poor neighborhoods by health insurance: 
Breast cancer care and survival in California, 1996 to 2011. Int J Equity Health 2013, 
12:6. 
25. Haji-Jama S, Gorey KM, Luginaah IN, Balagurusamy MK, Hamm C: Health insurance 
mediation of the Mexican American non-Hispanic white disparity on early breast 
cancer diagnosis. SpringerPlus 2013, 2:285. 
26. Richter NL, Gorey KM, Haji-Jama S, Luginaah IN: Care and survival of Mexican 
American women with node negative breast cancer: Historical cohort evidence of health 
insurance and barrio advantages. J Immigr Minor Health. in press. 
27. Gorey KM, Luginaah IN, Bartfay E, Fung KY, Holowaty EJ, Wright FC, Hamm C, 
Kanjeekal SM: Effects of socioeconomic status on colon cancer treatment accessibility 
and survival in Toronto, Ontario, and San Francisco, California, 1996—2006. Am J 
Public Health 2011, 101:112–119. 
28. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M: American 
Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th edition. New York: 
Springer- Verlag; 2002. 
29. Brant MK, Ziegler KL: California Cancer Reporting System Standards: Abstracting and 
Coding Procedures for Hospitals (Vol 1. 13th edition. Sacramento, CA: California Cancer 
Registry; 2013. 
30. Hosmer DW, Lemeshow S: Applied Logistic Regression. 2nd edition. New York: John 
Wiley & Sons; 2000. 
31. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE: Regression Methods in 
Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. 2nd edition. New 
York: Springer; 2012. 
32. Shapiro T, Meschede T, Osoro S: The roots of the widening racial wealth gap: 
Explaining the black-white economic divide. Waltham, MA: Institute on Assets and Social 
Policy, Brandeis University; 2013. 
33. Shapiro TM: The hidden cost of being African American: How wealth perpetuates 
inequality. New York: Oxford University Press; 2004. 
34. US Cancer Statistics Working Group: United States Cancer Statistics: 1999–2007 
Incidence and Mortality. Atlanta, GA: Centers for Disease Control and Prevention, and 
National Cancer Institute; 2010. 
35. US Census Bureau: Current Population Survey. Annual Social and Economic 
Supplement: 2011. Washington, DC: US Government Printing Office; 2012. 
36. Greenland S: Applications of stratified analysis methods. In Modern Epidemiology, 
283–302. Edited by Rothman KJ, Greenland S, Lash TL. Philadelphia, PA: Lippincott, 
Williams and Wilkins; 2008. 
37. Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli MT, 
Ebrahim S, Ezzati M, Salomon JA, Kreiser JG, Hogan M, Murray CJL: The burden of 
disease and injury in the United States 1996. Popul Health Metr 2006, 4:11. 
38. Shankaran V, Jolly S, Blough D, Ramsey SD: Risk factors for financial hardship 
patients receiving adjuvant chemotherapy for colon cancer: A population-based 
exploratory analysis. J Clin Oncol 2012, 30:1608–1614. 
39. Cress RD, Zaslavsky AM, West DW, Wolf RE, Felter MC, Ayanian AZ: Completeness 
of information on adjuvant therapies for colorectal cancer in population-based cancer 
registries. Med Care 2003, 41:1006–1012. 
40. Mallin K, Palis BE, Watroba N, Stewart AK, Walczak D, Singer J, Barron J, Blumenthal 
W, Haydu G, Edge SB: Completeness of American cancer registry treatment data: 
Implications for quality of care research. J Am Coll Surg 2013, 216:428–437. 
41. Chan JK, Gomez SL, O’Malley CD, Perkins CI, Clarke CA: Validity of cancer registry 
Medicaid status against enrollment files: Implications for population-based studies of 
cancer outcomes. Med Care 2006, 44:952–955. 
42. Hall S, Schulze K, Groome P, Mackillop W, Holowaty E: Using cancer registry data 
for survival studies: the example of the Ontario cancer registry. J Clin Epidemiol 2006, 
59:67–76. 
43. Verrill C: Assessing the Reliability and Validity of Primary Payer Information in Central 
Cancer Registry Data. Quebec City: Annual meeting of the North American Association of 
Central Cancer Registries; 2010. 
44. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH: Bias due to 
misclassification in the estimation of relative risk. Am J Epidemiol 1977, 105:488–495. 
45. Jurek AM, Greenland S, Maldonado G: How far from non-differential does exposure 
or disease misclassification have to be to bias measures of association away from the 
null? Int J Epidemiol 2008, 37:382–385. 
46. Brown GW, Mood AM: On median tests for linear hypotheses. In Proceedings of the 
Second Berkeley Symposium on Mathematical Statistics and Probability, 159–66. Edited by 
Neyman J. Los Angeles, CA: University of California Press; 1951. 
